Switzerland-based biopharma start-up Enzyvant has gained a double fast track status from the FDA for its new rare disease candidate RVT-802. The investigational tissue-based therapy is for the ...
Düsseldorf District Court issues preliminary injunction against Beijing Hanbaihan Medical Devices Co., Ltd. regarding ...
In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback